SBIR/STTR Research Award

Novel deep learning strategy to better predict pharmacological properties of candidate drugs and focus discovery efforts

Award identifier 78e6fadcc52e36b4bf8347a4de9b76af1792e1f7fd3ebcfce60d40f87b40f2c0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,830

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
COLLABORATIVE DRUG DISCOVERY, INC.
Proposal award date
2018-08-01
Contract end date
2019-05-31
UEI
KC1DAXHM8424
Solicitation number
PA17-302
Topic code
100

Research abstract

PROJECT SUMMARY Collaborative Drug DiscoveryIncCDDproposes to develop a novel approach based on deep learning neural networks to encode molecules into chemically rich vectorsWe will first apply this representation to build more powerful computational models that can more accurately predict properties such as bioactivityADMEToxand pharmacokinetics across libraries of molecular structuresThe ultimate goal is to leverage this representation to generate novel compounds with better combinations of propertiesBoth of these capabilities will help scientists to accelerate discovery of new drugs broadly across many therapeutic areasScientists engaged in drug discovery research from academic laboratories to large pharmaceutical companies rely on computational QSAR models to predict pharmacologically relevant properties and obviate the need to perform expensivetime consuming assaysmany of which require animal studiesfor every molecule of interestSome propertiese glogPcan now be modeled with such high confidence that the models have replaced the need to perform the assaysbut many other critical propertiese gsolubilityADMEPKhERGremain far from this goalWe expect that our proposed chemically rich vectors will significantly advance the state of the art beyond what can be achieved with conventional descriptors and fingerprintsImproved models will enable researchers to select lead candidate series more effectivelyexplore chemical space around leads to generate novel IP more efficientlyreduce failure rates for compounds advancing through the drug discovery pipelineand accelerate the entire drug discovery processThese benefits will be realized broadly across most therapeutic areasOur central innovation is a novel computational strategyfirst develop a deep learningDLmodel optimized to best capture the essential structural and chemical features of moleculesstarting from the most natural structural representationthen validate the DL model by applying it to improve QSAR modeling of pharmacological propertiesand finally extend it to generate previously unknown molecules that have superior propertiesthe so calledinverse QSARproblemwhich is the Holy Grail of computational medicinal chemistryOthers have unsuccessfully tried to leap directly to solve the inverse QSAR problemWe propose a more patient and methodical approach that will allow the neural network to perform self supervised training to learn about chemical structures and properties from readily availableextremely large datasetsthen transfer this learning to improve modelingonly after establishing this solid foundation do we intend to apply the models to attempt inverse QSARPrior attempts in this area have also relied on neural network architectures designed originally for language processingWe will design a new architecturemore akin to neural network architectures that have proven most successful at image classificationand optimize it to directly process themolecular graphthat represents the relationship of atoms and bonds in molecules PROJECT NARRATIVE The proposed project will create novel computational tools that will help researchers to understand whether potential new drugs are likely to be both safe and effectiveand identify similar compounds that are likely to be safer and more effective against the same targetThis innovative capability will help to accelerate the discovery and development of novel and improved drugs against a wide range of diseases!

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

17 SBIR/STTR records share this UEI (2010–2022). Reported award amounts total $14,412,575. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.